Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant milestone by dosing the first patients in its REVERTIPF trial. The 12-week, randomized, double-blind study is designed to assess the safety and clinical efficacy of TTI-101. This novel STAT3 inhibitor is being tested at three distinct doses, […]
Bristol Myers Squibb (BMS) said that BMS-986278 has succeeded in lowering the rate of lung function decline in idiopathic pulmonary fibrosis patients in a phase 2 clinical trial. BMS-986278, which is an oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, is now expected to advance into phase 3 clinical development in idiopathic pulmonary fibrosis. The mid-stage […]
Redx Pharma, a UK-based clinical-stage biotechnology company, and Jounce Therapeutics, a Nasdaq-listed clinical-stage immunotherapy company, have agreed to merge in an all-stock deal that values the combined group at $425 million. The combined group will operate as Redx Inc., which will trade on Nasdaq under the ticker REDX. It will be led by the incumbent […]
GRI Bio, a privately held clinical stage biotech company, will merge with a wholly-owned subsidiary of Nasdaq-listed Vallon Pharmaceuticals in an all-stock transaction. The combined entity is expected to operate as GRI Bio, Inc., and advance GRI Bio’s pipeline of natural killer T (NKT) cell regulators for the treatment of multiple inflammatory, autoimmune, and fibrotic […]
AbbVie has acquired DJS Antibodies, a privately-held UK-based biotech company, in an all-cash transaction valued at approximately $255 million, in a move to further strengthen its immunology pipeline. DJS Antibodies discovers and develops antibody drugs that target difficult-to-drug disease-causing proteins like G protein-coupled receptors (GPCRs). Through the transaction, AbbVie has acquired DJS-002, which is DJS […]
UK-based biotech company Redx Pharma said that it has received a milestone payment of $9 million from AstraZeneca following the initiation of a phase 1 clinical trial of AZD5055 (RXC006). AZD5055 is a porcupine inhibitor, which is targeted at fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and others. Redx Pharma had out-licensed the porcupine […]
Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA) for Nintedanib Capsules, 100mg, and 150mg. Nintedanib Capsules is the generic version of Ofev Capsules (nintedanib), 100mg and 150mg, owned by Boehringer Ingelheim Pharmaceuticals. Ofev is approved to be used in patients with idiopathic pulmonary fibrosis (IPF), […]
Galecto, a Danish biotech company, has raised $64 million in an equity financing round, for developing novel treatments for fibrosis and cancer. Led by Soleus Capital and co-led by Eir Ventures, the funding round is said to strengthen the existing cash balance of Galecto, extending its cash runway into late 2022. The financing round saw […]
Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas of central nervous system, metabolic, cardiovascular, and inflammatory diseases. According to the British Virgin Islands-incorporated special purpose acquisition company, the equity value of the combined company post its merger with […]
Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a deal worth up to $1.39 billion, as per the latest pharma acquisition news. The acquisition will give full rights for the Swiss pharma giant to Promedior’s portfolio of molecules targeting serious fibrotic diseases, including PRM-151, which holds […]